154 related articles for article (PubMed ID: 37129856)
1. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.
McKenna M; Epperla N; Ghobadi A; Liu J; Lazaryan A; Ibrahim U; Jacobson CA; Naik SG; Nastoupil L; Chowdhury SM; Voorhees TJ; Jacobs MT; Farooq U; Osman K; Olszewski AJ; Ahmed S; Evens AM
Br J Haematol; 2023 Jul; 202(2):248-255. PubMed ID: 37129856
[TBL] [Abstract][Full Text] [Related]
2. CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.
Portuguese AJ; Gauthier J; Tykodi SS; Hall ET; Hirayama AV; Yeung CCS; Blosser CD
Bone Marrow Transplant; 2023 Apr; 58(4):353-359. PubMed ID: 36575360
[TBL] [Abstract][Full Text] [Related]
3. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.
Krishnamoorthy S; Ghobadi A; Santos RD; Schilling JD; Malone AF; Murad H; Bartlett NL; Alhamad T
Am J Transplant; 2021 Feb; 21(2):809-814. PubMed ID: 33089906
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).
Kline K; Chen W; Kallen ME; Koka R; Omili D; Fan X; Iraguha T; Gebru E; Dishanthan N; Baker JM; Dietze KA; Yared JA; Hankey K; Dahiya S; Niederhaus SV; Dunleavy K; Hardy NM; Luetkens T; Rapoport AP; Atanackovic D
Hum Vaccin Immunother; 2023 Aug; 19(2):2216116. PubMed ID: 37278257
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
6. CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review.
Hernani R; Sancho A; Amat P; Hernández-Boluda JC; Pérez A; Piñana JL; Carretero C; Goterris R; Gómez M; Saus A; Ferrer B; Teruel AI; Terol MJ; Solano C
Curr Res Transl Med; 2021 Oct; 69(4):103304. PubMed ID: 34303899
[TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Wang T; Feng M; Luo C; Wan X; Pan C; Tang J; Xue F; Yin M; Lu D; Xia Q; Li B; Chen J
Cell Transplant; 2021; 30():963689721996649. PubMed ID: 33631963
[TBL] [Abstract][Full Text] [Related]
9. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
10. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series.
Luttwak E; Hagin D; Perry C; Wolach O; Itchaki G; Amit O; Bar-On Y; Freund T; Kay S; Eshel R; Avivi I; Ram R
Bone Marrow Transplant; 2021 May; 56(5):1031-1037. PubMed ID: 33230187
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
13. Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy.
Dang BN; Ch'ng J; Russell M; Cheng JC; Moore TB; Alejos JC
Pediatr Transplant; 2021 Aug; 25(5):e13861. PubMed ID: 33002249
[TBL] [Abstract][Full Text] [Related]
14. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
15. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
Fu S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
[TBL] [Abstract][Full Text] [Related]
17. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
[TBL] [Abstract][Full Text] [Related]
18. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
